STOCK TITAN

Liquidia Corp - LQDA STOCK NEWS

Welcome to our dedicated news page for Liquidia (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Liquidia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Liquidia's position in the market.

Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) has received a favorable ruling from the Court of Appeals for the Federal Circuit, affirming all rulings by the United States District Court for the District of Delaware in the litigation filed by United Therapeutics (UTHR). The case focused on the infringement of U.S. Patent No. 10,716,793 ('793 Patent) by Liquidia's YUTREPIA™ (treprostinil) inhalation powder. The ruling does not affect the previous decision by the Patent Trial and Appeal Board (PTAB) that all claims in the '793 patent are unpatentable, which was re-affirmed in February 2023. Liquidia will now seek final regulatory approval for YUTREPIA pending the appeal of the '793 IPR decision by the Federal Circuit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
none
-
Rhea-AI Summary
Liquidia Corporation reported financial results for Q1 2023, with revenue of $4.5 million, a 28.6% increase from Q1 2022. Cash totaled $94.4 million as of March 31, 2023. The company secured access to additional capital with revenue interest financing, with the potential to receive up to $100 million. Liquidia also provided updates on legal appeals related to patent litigation. Net loss for Q1 2023 was $11.7 million, compared to $15.9 million in Q1 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.25%
Tags
Liquidia Corp

Nasdaq:LQDA

LQDA Rankings

LQDA Stock Data

1.06B
49.94M
12.42%
51.22%
9.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Durham

About LQDA

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.